#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cold type haemolytic anaemia Mantle cell lymphoma stage III Rhabdoid tumour Acute lymphocytic leukaemia Phenylketonuria Lymphatic malformation Primary hyperoxaluria Pelizaeus-Merzbacher disease Acute lymphocytic leukaemia recurrent Depression Erdheim-Chester disease Arrhythmia Gaucher's disease type I Cutaneous T-cell lymphoma Chronic cutaneous lupus erythematosus More trials…

    Learn about Rare Diseases

    Primary immunodeficiency syndrome – Trials in Disease Andersen-Tawil syndrome – Diagnostics Richter’s syndrome – Basic Information Alport’s syndrome Marginal zone lymphoma refractory Basal cell naevus syndrome – Life with Disease Stevens-Johnson syndrome – Life with Disease Undifferentiated sarcoma – Life with Disease Prolymphocytic leukaemia – Basic Information Rhabdoid tumour – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Pioglitazone Autologous Chondrocytes Cannabis Sativa Flower Heparin Lymecycline Elacestrant Rigosertib Sodium Mifepristone Gs-4182 Nafarelin ATIGOTATUG Piflufolastat (18F) 177LU-PSMA-I&T Trametinib Altizide Sodium Phosphate Dodecahydrate Fluoroestradiol F-18 Mebufotenin ULVIPRUBART Abiraterone More therapies…

    Learn about Your Condition

    Rhabdomyosarcoma recurrent Emphysema Cutaneous T-cell lymphoma Acoustic neuroma Urinary incontinence Alcoholic liver disease Pleural mesothelioma malignant Pyoderma gangrenosum Mite allergy Bipolar disorder Osteomyelitis Chronic myeloid leukaemia Neuromuscular scoliosis MELAS syndrome Pancreatitis chronic More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Neoplasms

  • Study of MK-1084 and Pembrolizumab for First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation and High PD-L1 Levels

    Recruiting

    3 1 1
    Investigated Drugs:
    • Mk-1084
    • Pembrolizumab
    Austria Bulgaria France Germany Greece Italy +4

  • Study of LY3484356 (imlunestrant) with Tamoxifen Citrate and Goserelin Acetate in Premenopausal Women with ER‑Positive, HER2‑Negative Early Breast Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast neoplasm
    Investigated Drugs:
    • Ly3484356
    • Tamoxifen Citrate
    • Goserelin Acetate
    Belgium France Germany Italy

  • Cevostamab, Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 1‑3 Lines of Therapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Carfilzomib
    • Cevostamab
    • Elotuzumab
    Czechia Denmark France Germany Greece Italy +2

  • Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Cabozantinib
    Denmark Finland France Italy The Netherlands Poland +2

  • Safety Study of VCN-01 with nab‑Paclitaxel and Gemcitabine in Newly Diagnosed Metastatic Pancreatic Cancer Patients

    Recruiting

    2 1 1
    Investigated Drugs:
    • Genetically Modified Human Adenovirus Encoding Human Ph20 Hyaluronidase
    Spain

  • Study of telisotuzumab adizutecan plus drug combination in adults with refractory metastatic colorectal cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Tipiracil
    • Trifluridine
    • Bevacizumab
    Belgium Germany Greece Portugal Spain
1 2 3 … 526
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!